Pieris Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

August 4, 2022 7:00 AM

COMPANY TO HOST AN INVESTOR CONFERENCE CALL ON THURSDAY, AUGUST 4, 2022 AT 8:00 AM EDTAdjustments to PRS-060/AZD1402 phase 2 study design boost enrollment rate and facilitate a topline readout by 3Q23Cinrebafusp alfa (PRS-343) demonstrating clinical benefit in HER2-expressing gastric cancer patients, but Company will cease enrollment to focus its resourcesFirst-in-human regulatory submission for PRS-220 achieved, with first subject dosing...

Read more

RepliCel Announces Material Patent Milestones in Key Markets

August 4, 2022 6:00 AM

New DermaPrecise™ patent application and patents granted for tendinopathy and skin rejuvenation technologies in key marketsVANCOUVER, BC / ACCESSWIRE / August 4, 2022 / RepliCel Life Sciences Inc. (OTCPK:REPCF)(TSXV:RP)(FRA:P6P2) ("RepliCel" or the "Company"), a company developing novel, next-generation injection technologies as well as cell-based regenerative medicine products in aesthetics and orthopedics, is pleased to announce the...

Read more

enVVeno Medical Reports Second Quarter 2022 Financial Results and Provides Corporate Update

August 3, 2022 4:45 PM

Ended the quarter with $47.2 million in cash and investments - expected to fund operations through the end of 2024, including release of topline SAVVE pivotal trial dataIRVINE, CA / ACCESSWIRE / August 3, 2022 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today provided a corporate update and reported financial results for the second quarter...

Read more

Edesa Biotech to Participate at the Upcoming BTIG Biotech Conference

August 3, 2022 8:15 AM

TORONTO, ON / ACCESSWIRE / August 3, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that its executive management will participate in the upcoming BTIG Biotechnology Conference being held in New York, NY on August 8-9, 2022. The hybrid event will be held both virtually and in-person.Attendees who are interested in meeting with the company...

Read more

Apollo Endosurgery, Inc. Reports Record Global Revenue in Second Quarter 2022

August 2, 2022 4:01 PM

Grew global revenue 16% (20% in constant currency) as adoption increased across all product linesSecured FDA marketing authorization for Apollo ESGTM and Apollo REVISETMAUSTIN, TX / ACCESSWIRE / August 2, 2022 / Apollo Endosurgery, Inc. ("Apollo") (Nasdaq:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, today announced financial results for the second quarter ended June 30, 2022 and recent...

Read more

Black Bird Biotech Readies for Illinois State Fair and Du Quoin State Fair in America’s Heartland and Cannabis Conference 2022 in Las Vegas

August 2, 2022 9:15 AM

FLOWER MOUND, TX / ACCESSWIRE / August 2, 2022 / Black Bird Biotech, Inc. (OTC:BBBT), manufacturer and distributor of plant-based MiteXstreamTM biopesticide, announced that its marketing team will be exhibiting MiteXstreamTM at the Illinois State Fair in Springfield from August 11th to the 21st, the Du Quoin (Illinois) State Fair from August 26th to September 5th and Cannabis Conference 2022 in Las Vegas from August 23th to the 25th."Exhibiting...

Read more

Xenetic Biosciences, Inc. and VolitionRx Limited Collaborate to Develop NETs-Targeted Adoptive Cell Therapies for the Treatment of Cancer

August 2, 2022 8:05 AM

FRAMINGHAM, MA / ACCESSWIRE / August 2, 2022 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard-to-treat cancers, and VolitionRx Limited (NYSE AMERICAN:VNRX) ("Volition"), a multi-national epigenetics company, today announced a research and development collaboration to develop Neutrophil Extracellular Traps ("NETs") targeted, adoptive...

Read more

DermaPrecise(TM) Injection System Shown to Produce Consistently High Cell Count and Viability for Cell Therapy Injections

August 2, 2022 6:00 AM

Independent Testing Performed by Innovacell Demonstrates the DermaPrecise™ Control Leads to Unparalleled Post-Injection Cell Survival and Viability ConsistencyVANCOUVER, BC / ACCESSWIRE / August 2, 2022 / RepliCel Life Sciences Inc. (OTC PINK:REPCF)(TSXV:RP)(FRA:P6P2) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, announced today it has received test results showing that...

Read more

BioInvent Enrolls First Patient in Phase 1/2a Trial of BI-1607 in HER2 Positive Solid Tumors

August 1, 2022 9:15 AM

LUND, SWEDEN / ACCESSWIRE / August 1, 2022 / BioInvent International (STO:BINV)Study of BI-1607 in combination with trastuzumab in HER2 positive solid tumorsFirst patient recruited in SpainPreclinical data indicate BI-1607 enhances the effect of trastuzumab (Herceptin®)BioInvent's fifth clinical trial; four distinct drug candidates in ongoing trialsBioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on...

Read more

Biovica Receives FDA Approval for DiviTum(R)TKa

July 30, 2022 7:10 AM

UPPSALA, SWEDEN / ACCESSWIRE / July 30, 2022 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II).Biovica, active in cancer diagnostics, today announces that FDA has granted 510(k) clearance for the product DiviTum®TKa as an aid in monitoring disease progression in previously diagnosed hormone receptor positive, metastatic postmenopausal female breast cancer patients."We are excited to have received the formal approval from FDA...

Read more

Apollo Endosurgery Announces Publication in the Lancet of Landmark Study for the Endoscopic Sleeve Gastroplasty Procedure

July 29, 2022 7:00 AM

Publication of MERIT Study Follows FDA Market Authorization of Apollo ESG™AUSTIN, TX / ACCESSWIRE / July 29, 2022 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures, announced today the electronic publication of the landmark Multi-center ESG Randomized Interventional Trial (MERIT) Study in The Lancet.(1)The MERIT study is a multi-center,...

Read more

Change in the Number of Shares and Votes in BioInvent International AB

July 29, 2022 2:20 AM

LUND, SWEDEN / ACCESSWIRE / July 29, 2022 / BioInvent International (STO:BINV)Lund, Sweden - July 29, 2022 - BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV) today announced that the company's total number of shares as per July 29, 2022 amounts to 64,967,884 shares, corresponding to an equal number of votes. The increase in the number of shares and votes results from the directed issue of approximately SEK 298.9...

Read more

Media Alert: BrainChip Talks ML at the Edge with Jan Jongboom on Latest 'This is our Mission' Podcast

July 28, 2022 6:50 PM

LAGUNA HILLS, CA / ACCESSWIRE / July 28, 2022 / BrainChip Holdings Ltd (ASX:BRN)(OTCQX:BRCHF)(ADR:BCHPY), the world's first commercial producer of neuromorphic AI IP, today announced that Jan Jongboom, co-founder and CTO at Edge Impulse, is the featured guest on the latest "This is our Mission" podcast. Jongboom joins BrainChip Vice President of Worldwide Sales, Rob Telson to discuss how machine learning on neuromorphic computing can make IoT...

Read more

Pieris Pharmaceuticals to Host Second Quarter 2022 Investor Call and Provide Corporate Update on August 4, 2022

July 28, 2022 7:20 AM

BOSTON, MA / ACCESSWIRE / July 28, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that it will host a second quarter 2022 investor call on Thursday, August 4, 2022 at 8:00 AM EDT to discuss financial results and provide a corporate update.To...

Read more

Enzolytics Announces the International Patent Office Search Report finding Novelty and Inventiveness in the Company's Pending International Patent Application Covering its anti-HIV Monoclonal Antibodies.

July 28, 2022 6:30 AM

COLLEGE STATION, TX / ACCESSWIRE / July 28, 2022 / Enzolytics, Inc. (OTC PINK:ENZC) ("ENZC" or the "Company"). In the first Official Action on the Company's International Patent Application covering its discovery and exclusive claim to conserved antigens and epitopes of the HIV virus, the PCT International Search Report concluded that inventions claimed therein are novel and inventive and thus will expectedly be issued in final international...

Read more

RepliCel’s Manufacturing Inspected by Japan’s PMDA

July 28, 2022 6:00 AM

After over a year of pandemic-related delays, representatives of Japan's PMDA, attended at the Company's contract manufacturing facility, Innovacell, to review the manufacturing of RepliCel's NBDS cell therapy productsVANCOUVER, BC / ACCESSWIRE / July 28, 2022 / RepliCel Life Sciences Inc. (OTCPINK:REPCF)(TSXV:RP)(FRA:P6P2) ("RepliCel" or the "Company"), a company developing novel, next-generation injection technologies as well as regenerative...

Read more

Ensysce Biosciences Announces Positive Bioequivalence (BE) Study Data of Novel "TAAP" Opioid PF614 and Provides Timing of Corporate Update Call

July 27, 2022 8:05 AM

~ BE Study of PF614 Represents Critical Progress Toward FDA Approval ~~ Supports the 505(b)(2) Regulatory Path for Clinical Development of PF614 ~SAN DIEGO, CA / ACCESSWIRE / July 27, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, announced today the data from the Part...

Read more

Notice of Annual General Meeting in Biovica International AB

July 27, 2022 2:20 AM

UPPSALA, SWEDEN / ACCESSWIRE / July 27, 2022 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II)The shareholders of Biovica International AB, reg. no. 556774-6150, (the "Company") are hereby invited to the annual general meeting on Wednesday 31 August 2022. The board of directors has decided that the annual general meeting shall only be conducted by advance voting (postal voting) on the basis of temporary legislation.Information on the...

Read more

Plandai Biotechnology, Inc. Announces Termination of Non-Binding Letter of Intent

July 27, 2022 12:00 AM

SAN DIEGO, CA / ACCESSWIRE / July 27, 2022 / Plandai Biotechnology, Inc. ("Plandai" or the "Company") announces the termination of its non-binding letter of intent dated May 23, 2022, with Ms. Jessie Chiang, license holder of the worldwide rights, exclusive of Taiwan, of the Puriblood Leukocyte Reduction Blood Filtration System. As previously discussed in the Company's May 23, 2022, press release, the Company and Ms. Chiang intended to complete...

Read more

CORRECTION: Independent Laboratory Test Results Confirm Value of DermaPreciseTM Injection Consistency in Clinical Simulation Testing

July 26, 2022 4:45 PM

This press release replaces the press release disseminated July 26, 2022 at 06:00 EDT. The press release contained the wrong image - one intended for a future press release. The corrected press release with the proper image is below:VANCOUVER, BC / ACCESSWIRE / July 26, 2022 / RepliCel Life Sciences Inc. (OTC PINK:REPCF) (TSXV:RP) (FRA:P6P2) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and...

Read more